Delivery Order SPE2DB25D3202-SPE2DB25FTBLY
- Not listed
- The Defense Logistics Agency awarded a $4,376.49 delivery order to AmerisourceBergen Drug Corp for AJOVY (fremanezumab) 225 mg/1.5 mL auto-injector auto-injectors, with delivery to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 14, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,073.80 to AmerisourceBergen Drug Corp for AJOVY 225 mg/1.5 mL auto-injector units on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order, which is not subject to a set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of AJOVY 225 mg/1.5 mL syringes, with a ceiling value of $1,092.00. This competitive, firm fixed-price delivery order was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AJOVY is a prescription medication used primarily for the treatment of...
- The Defense Logistics Agency Troop Support Medical awarded a $348 firm fixed price delivery order to Amerisourcebergen Drug Corporation for AJOVY 225 MG/1.5 ML syringes. The single syringes will be delivered to Amerisourcebergen's facility in Conshohocken, Pennsylvania over a one day period from July 10-11, 2023. Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, will serve as the prime contractor on this delivery order issued against an existing DLA medical product...
- The Defense Logistics Agency awarded a $1,092.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for AJOVY 225 mg/1.5 mL auto-injector units on September 9, 2025, with an ultimate completion date of September 10, 2025. AJOVY is a prescription medication used for chronic weight management. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ajovy 225 mg/1.5 mL auto-injectors, with a ceiling value of $1,092.00 and a completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,522 delivery order to Amerisourcebergen Drug Corporation for AJOVY 225 MG/1.5 ML syringes. The firm fixed price order is for a quantity of 1.5 ML syringes to be delivered to a facility in Conshohocken, Pennsylvania between September 15-18, 2023. Amerisourcebergen will serve as the prime contractor, with performance taking place at its Corporate Office Division location. The delivery order was issued under an unspecified agency-wide contract vehicle and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,847.18 to AmerisourceBergen Drug Corp's Corporate Office Division for the supply of AJOVY 225 MG/1.5 ML AUTOINJECT 1.5ML, a pharmaceutical product. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which provides a comprehensive range of medical commodities to support military treatment programs and facilities...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $1,092.00 for AJOVY 225MG/1.5ML, a pharmaceutical product for federal medical procurement. The award was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, under a Firm Fixed Price contract type with no set-aside designation. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $348,330 firm fixed price delivery order to Amerisourcebergen Drug Corporation for AJOVY 225 MG/1.5 ML syringes. The single award was issued under an undisclosed government-wide acquisition contract vehicle or blanket purchase agreement held by Amerisourcebergen. Performance will occur at the prime contractor's facility in Conshohocken, Pennsylvania with delivery required by August 21, 2023 to support DLA programs. No set aside designation or subcontractors...
- SPE2DB25D3202Indefinite Delivery Contract
- SPE2DB25D3202-SPE2DB25FTBLYDelivery Order
The Defense Logistics Agency (DLA) awarded a $1,943.71 firm fixed price delivery order to AmerisourceBergen Drug Corp for AJOVY (fremanezumab) 225 mg/1.5 mL syringes on September 26, 2025, with completion targeted for September 29, 2025. This non-set-aside award represents a pediatric migraine prevention medication delivery to support federal medical supply requirements. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, valued at $999,999,999.00 through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems and other federal agencies, including the Defense Health Agency and U.S. Coast Guard. The company's demonstrated capability to competitively win federal pharmaceutical contracts across multiple therapeutic domains, combined with its established relationship with DLA, positions it as a critical provider within the federal medical procurement landscape.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/26/25 |